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Background: Apolipoprotein E (apo E) plays a major role in lipid metabolism, obesity and accordingly in
development of diabetes and coronary heart disease (CHD). Our main objective was to evaluate the association
between apo E gene polymorphism with anthropometric measures.
Methods: Participants were selected from zone 17 Tehran/Iran. We assessed height, weight, body mass index (BMI),
waist circumference (WC), blood pressure, serum fasting blood sugar, total cholesterol and triglycerides. Genotyping
for apo E gene polymorphism was carried out using PCR-RFLP technique.
Results: Among total study population (n=311), 156 subjects were diabetic. The apo E3/E3 was the most common
genotype in our population while E2 and E4 alleles had lower frequencies, respectively. After adjustment for
diabetes, the apo E2 and E4 alleles were significantly associated with hypercholesterolemia and WC, respectively
(p= 0.009, 0.034). This association was also related to sex and age. The probability of having abdominal obesity in
E4 allele carriers was increased from 0.22 to 8.12 in women and to 3.08 in age ≥ 50 years.
Conclusions: Apo E polymorphism had significant influences on WC and total cholesterol level in patients with
type 2 diabetes. This study highlights the importance of lifestyle modifications which may be more beneficial in
hypercholesterolemic women carriers of E2 and E4 alleles concomitant central obesity.
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The human apo E is polymorphic and its genetic vari-
ation can affect its anti atherosclerotic effects [1]. The
common variants of apo E polymorphism include E2,
E3, and E4 allelic isoforms and six corresponding geno-
types (E3/E3, E3/E4, E2/E3, E4/E4, E2/E4, and E2/E2,
ranked from most to least common). Previous studies
have shown that unlike the E3 allele, the E4 allele is
associated with hypercholesterolemia, increased levels of
LDL, HDL and atherosclerosis. Whereas E2 allele is
related to increased plasma concentrations of triglycer-
ide (TG) and lipoprotein remnants, decreased LDL [2,3],* Correspondence: amolimm@tums.ac.ir
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distribution, and reproduction in any mediumand pro- or anti atherogenic effects [1]. So, genetic poly-
morphism of apo E can contribute to the variation in
lipoproteins concentration. The meta-analysis of 82
studies on lipid levels and 121 studies on coronary out-
comes has identified a linear relationship of apo E gene
polymorphism with both LDL levels and coronary risk
to some extent. They showed that carriers of E2 allele
have a 20% lower risk of coronary disease and E4 car-
riers have a slightly higher risk, compared with indivi-
duals with the E3/E3 genotype [4]. Similar results have
been previously reported in other studies [3,5].
It has been suggested that the apolipoprotein E (apo E)
gene polymorphism may be associated with predispos-
ition to diabetic complications (both micro- and macro-
vascular complications). This association was shown
between apo E gene polymorphism and diabetic nephro-
pathy, but not for diabetic retinopathy in type 1 diabetesed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tects from macro- and microvascular complications and
E4 allele tends to increase the risk for vascular complica-
tions [7]. As apo E plays an important role in lipid metab-
olism and on the other hand hypercholesterolemia is an
independent risk factor for premature CHD, apo E may
be an important risk determinant for CHD in diabetic
and non diabetic subjects [8]. Also, it was shown that apo
E polymorphism has different effects in diabetic and non-
diabetic populations [9,10].
Recent evidence from both animal and human studies
showed the important role of apo E gene in the develop-
ment of obesity and insulin resistance [11]. Obesity is a
worldwide health problem [12], and associated with sev-
eral diseases such as type 2 diabetes mellitus (T2DM),
hypertension and CHD [12]. In addition, epidemiological
and population studies have established a direct correl-
ation between obesity and development of cardiovascu-
lar disease [13]. The clustering of several clinical
phenotypes including hypertension, dyslipidemia, obes-
ity, and diabetes in the same subject may be due to a
shared genetic background [14,15]. However, the import-
ance of different risk factors for T2DM differs between
ethnic populations [16]. In this study we aimed to deter-
mine the influence of apo E gene polymorphism on an-
thropometric measures in a group of Iranian with ethnic
who had T2DM in comparison non-diabetes subjects.
Methods
Study population
Study subjects were recruited from zone 17 of Tehran/
Iran. The inclusion criteria were all of subjects who inter-
est to enroll in the study. This study comprised of 311
subjects; 155 non-diabetics and 156 diabetics from
the similar area. T2DM was diagnosed according to
American Diabetes Association criteria [17]. After
obtaining informed consent, a personal and demo-
graphic questionnaire was filled for each patient. Then
height, weight, waist circumference (WC) and blood
pressure were measured and recorded.
Body Mass Index (BMI) was calculated based on the fol-
lowing formula; body weight /square height (kg/m2).
Obesity was defined as BMI ≥ 30 kg/m2 according to
WHO recommendations [14]. In each subject (at standing
position), WC was considered as the widest measure with
a measuring tape between the margin of lower limb and
crest of iliac, based on centimeter by the same investiga-
tor. Abdominal obesity was defined as a WC > 102 cm in
men, and > 88 cm in women [18]. Systolic and diastolic
blood pressures were measured in right arm at sitting pos-
ition after 5 – 10 – min rest. Hypercholesterolemia and
hypertriglyceridemia were defined as total cholesterol ≥
200 and triglyceride ≥ 150 mg/dl based on definition of
hyperlipidaemia in NCEP ATP III a [19].The study was approved by the Ethics Committee of
Tehran University of Medical Sciences of Iran.
Laboratory methods
Levels of TG and cholesterol were tested for all our
subjects using standard enzymatic methods (Pars
Azmun, Iran). DNA was extracted from leukocytes
using salting-out method [20]. Genomic DNA was amp-
lified by PCR with the following primers F5’-TCCAA
GGAGC TGCAG GCGGC GCA and R5’-GCCCC
GGCCT GGTAC ACTGC CA yielding a 218-bp DNA
fragment that spans both apo E polymorphic sites. Simul-
taneous digestion of the 218-bp amplified product by
AflIII and HaeII enzymes yielded 145-bp, 168-bp, and
195-bp fragments corresponding to apo E3, E2, and E4,
respectively.
Statistical analysis
Strength of association between different variables and
apo E gene polymorphism was estimated by Chi-square
and logistic regression using SPSS software, version 11.5.
P ≤ 0.05 was considered as significant in statistical
analysis.
Results
The age of the participants in the study was 25–65 years
and mean age was 46 ± 13 years. In this study 32.2% of
subjects were male and 67.8% were female.
Baseline characteristics in diabetic and non-diabetic
participants
The frequency of smokers, dyslipidemic, hypertensive,
diabetic subjects, and past history of CHD or T2DM in
the participants were 10.7, 55.5, 60.2, 50.2, 10 and 33%,
respectively. Baseline characteristics of participants
(n=311) are shown in Table 1. There was no significant
difference in distribution of apo E gene polymorphism
frequency in diabetics and nondiabetics (p= 0.414).
Distribution of apo E genotype frequencies and mean
level of anthropometric measures in diabetic and
non-diabetic participants
The frequency of different polymorphism of apo E gene in
our population is shown in Table 2. The mean level of an-
thropometric measures in subgroup of abnormal WC of
diabetics and nondiabetics was significantly higher than in
subgroup of normal WC which is shown in Table 2.
Apo E gene polymorphism association with
anthropometric measures in diabetics & non-diabetics
Coefficients of univariate and multivariate regression
models between independents variables (sex, age ≥ 50
years, apo E2/E3 or apo E4/E3 polymorphism versus apo
E3/E3, and T2DM) and dependent variables (BMI ≥ 30,
Table 1 Baseline characteristics in type 2 diabetic patients and non diabetic subjects
Variable T2DM (n=156) Non diabetic subjects (n=155) P Value
Sex (M/F) (n/%) 46(14.8)/ 110(35.4) 54(17.4)/ 101(32.5) 0.333
Apo (E3/E3)/ (E2/E3)/ (E4/E3) (n/%) 113(38.2)/16(5.4)/15(5.1) 118(39.9)/23(7.8)/11(3.7) 0.414
Age (yr) 49 ± 11 41 ± 13.7 <0.001*
BMI (kg/m2) 32.6 ± 4.6 25.7 ± 3.7 <0.001*
SBP (mmHg) 140 ± 24 124 ± 21 <0.001*
DBP (mmHg) 89 ± 13 80 ± 13 <0.001*
WC (cm) 97 ± 12 91 ± 13 <0.001*
FBS (mg/dl) 115 ± 60 94 ± 49 0.001*
TChol (mg/dl) 210 ± 48 202 ± 42 0.140
£TG (mg/dl) 240 ± 176 176 ± 151 <0.001*
Legend: T2DM: Type 2 Diabetes Mellitus, M/F: Male/Female, BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diastolic.
Blood Pressure, WC: Waist Circumference, FBS: Fasting Blood Sugar, TChol: Total Cholesterol, TG: Triglyceride.
*P≤0.05 was considered as significant in statistical analysis, T- test.
£ Analytic test was Mann–Whitney Test.
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cholesterol or triglycerides) are shown in Table 3.
BMI: The influence of sex on BMI ≥ 30 was independ-
ent of diabetes or apo E gene polymorphism. Central
obesity: Sex, aging, and apo E4 allele had significant in-
fluence on central obesity which these effects were
dependent to diabetes.
Hypertension: Aging had a significant influence on
hypertension dependent to diabetes.
Hypercholesterolemia: Sex, aging, and apo E2 allele
had significant influence on hypercholesterolemia which
these effects were independent of diabetes.
Hypertriglyceridemia: We didn’t find any significant
association between independent variables and
hypertriglyceridemia.
The details of all above mentioned results are shown
in Table 3.Table 2 Distribution of apo E genotype frequencies in type 2
Variable T2DM (n=156)
WC normal (n=51) WC abnormal (n=1




Age (yr) 52 ± 12 51 ± 10
BMI (kg/m2) 25.4 ± 3 32 ± 5
SBP (mmHg) 131 ± 20 143 ± 25
DBP (mmHg) 84 ± 13 90 ± 14
FBS (mg/dl) 125 ± 68 140 ± 67
TChol (mg/dl) 199 ± 46 215 ± 48
£TG (mg/dl) 241 ± 211 269 ± 197
Legend: T2DM: Type 2 Diabetes Mellitus, WC: Waist Circumference, waist circumfe
M/F: Male/Female, BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diasto
TG: Triglyceride.
* P≤0.05 was considered as significant in statistical analysis, T- test.
£££Ê£ Analytic test was Mann–Whitney Test.Discussion
The complex polygenic diseases such as diabetes could
be complicated by phenomena such as variable age at
onset disease, or environmental triggers [21]. Although,
some phenotypes such as BMI and insulin resistance
have been affected largely by genetic factors, others such
as abdominal obesity have been affected largely by
non-genetic factors, probably environmental [22,23]. So,
assessment characteristics of well defined phenotypic
abnormalities could show clearly the association be-
tween genome and environment. On the other word by
assessment the association between apo E gene poly-
morphism and anthropometric measures as risk factors
of diabetes, it is possible to determine the association
between apo E gene polymorphism and diabetes.
The role of apo E gene polymorphism in anthropomet-
ric measures has been studied in different populations.diabetic patients and non diabetic subjects
P Value Non diabetic subjects (n=155) P Value
05) WC normal (n=81) WC abnormal (n=73)
<0.001* 40(26)/ 41(26.6) 14(9.1)/ 59(38.3) <0.001*
) 0.005* 62(41.1)/11(7.3)/6(4) 56(37.1)/11(7.3)/5(3.3) 0.965
0.866 34 ± 10 46 ± 12 <0.001*
<0.001* 26 ± 4 33 ± 4 <0.001*
0.003* 119 ± 22 135 ± 21 <0.001*
0.007* 78 ± 13 88 ± 13 <0.001*
0.175 75 ± 8 80 ± 10 0.002*
0.042* 188 ± 38 219 ± 42 <0.001*
0.029* 135 ± 72 199 ± 133 <0.001*
rence is >88 cm in women and >102 cm in men is defined as abnormal,
lic Blood Pressure, FBS: Fasting Blood Sugar, TChol: Total Cholesterol,
Table 3 Coefficients of univariate and multivariate regression models between independents variables and obesity, abdominal obesity, hypertension, high
levels of total cholesterol and triglyceride
Variable Obesity (Y/N) Abdominal obesity (Y/N) Hypertension (Y/N) Hypercholesterolemia (Y/N) Hypertriglyceridemia (Y/N)





















Sex (Female/Male) 2.77* 3.07** 5.19* 8.12** 1.02 1.02 2.05* 2.10** 1.14 1.06
(1.67-4.58) (1.77-5.31) (3.10-8.70) (4.29-15.36) (0.63-1.64) (0.58-1.79) (1.26-3.32) (1.23-3.61) (0.70-1.86) (0.61-1.86)
Age (>50/<50 yr) 1.26 1.47 2.55* 3.08** 4.41* 3.26** 2.21* 2.05** 1.54* 0.91
(0.79-2.01) (0.87-2.51) (1.57-4.16) (1.64-5.78) (2.66-7.31) (1.86-5.72) (1.37-3.57) (1.19-3.51) (0.96-2.46) (0.52-1.58)
Apo (E2/E3)/apo
(E3/E3)
0.85 0.83 0.89 0.99 0.98 1.08 0.42* 0.36** 1.16 1.12
(0.43-1.68) (0.40-1.71) (0.45-1.79) (0.44-2.24) (0.49-1.96) (0.51-2.29) (0.21-0.84) (0.17-0.77) (0.58-2.30) (0.52-2.38)
Apo (E4/E3)/apo (E3/E3) 0.73 0.59 0.41* 0.22** 1.09 0.88 1.19 1.03 2.04* 1.96
(0.32-1.65) (0.25-1.38) (0.18-0.93) (0.08-0.56) (0.48-2.52) (0.36-2.15) (0.52-2.73) (0.44-2.44) (0.90-4.65) (0.81-4.74)
Legend: Obesity: BMI≥30 kg/m2, Abdominal obesity: waist circumference is >88 cm in women and >102 cm in men, Hypertension: blood pressure is>130/85 mmHg.
Hypercholesterolemia: Total cholesterol is >200 mg/dl, Hypertriglyceridemia: Triglyceride is >150 mg/dl, Y/N: yes/no, CI 95%: confidence interval 95%.
* P < 0.2 in binary regression with univariate model is considered for analysis by binary regression with multivariate model. On the other hand P>0.2 in univariate analysis can. not be considered for analysis with
multivariate model and are determined as NS.























Tabatabaei-Malazy et al. Journal of Diabetes & Metabolic Disorders 2012, 11:18 Page 5 of 7
http://www.jdmdonline.com/content/11/18Although this study is conducted in a small sample size,
this is the first study on association between apo E gene
polymorphism and anthropometric measures in Iranian
population. In this study Apo E3 was the most common
allele in our population, and E2 followed by E4 allele
have been found less frequent both in diabetics and non-
diabetics. These findings are in agreement with previous
reports [10,24]. So, the frequency of apo E polymorph-
ism could be reasonable different according to environ-
mental factors and lifestyle behaviors, obesity, gender,
population related differences (such as geographical dif-
ferences), presence of CHD, and even undertreatment
lipid lowering drugs [25-31].
In subgroup of patients with abnormal WC in our
study, all components of anthropometric measures were
higher than subgroup that had normal WC. Previous
evidence also supports our finding [32-34] which may be
related to insulin resistance. Our study was shown a sig-
nificant difference in distribution of apo E allele fre-
quency in patients stratified according to WC only in
diabetic group. Also, there was a significant influence for
apo E4 allele on central obesity. But this effect was non-
significant for apo E2 allele. Oh et al. [26] found a sig-
nificant correlation between WC and apo E4 allele in
women with a family history of diabetes which was inde-
pendent of hyperlipidemia. This suggests that mechan-
isms other than lipid pathways might be involved in apo
E action [35]. As the weight control is important for im-
proving insulin sensitivity and reducing CVD risk, there-
fore it might be speculated that in apo E4 carriers
weight control play crucial role in control of hypergly-
cemia and reducing CVD risk.
In our study, apo E2 allele was significantly asso-
ciated with hypercholesterolemia both in women and
in patients aged > 50 which was independent of dia-
betes. Also, lipid levels did not significantly differ be-
tween subjects with apo E3/E3 and apo E4/E3. This is
in agreement with our previous results and also
results by Pedro-Botet et al. who found significantly
higher level of total cholesterol in patients with E2
isoform [24,29]. In contrast, Oh et al. [26] found that
in men with family history of diabetes, apo E2 and
also apo E4 carriers had higher level of total and LDL
cholesterol compared to those with apo E3/E3, al-
though the difference was not significant. In addition,
they have found that in both sexes with no family
history of diabetes, apo E2 was associated with nor-
mal levels of total and LDL cholesterol [26]. It seems
the effect of apo E polymorphism on lipid metabolism
may vary according to genetic background. However,
the apo E polymorphism especially apo E4 seems to
be a risk factor for CHD development independent of
association with high level of total and LDL choles-
terol [35-39].An association between apo E2 allele and hypertrigly-
ceridemia has been consistently reported in healthy
populations [40-43]. Dallongeville et al. in their meta-
analyzes have shown that triglyceride concentration is
significantly higher in carrier of E2 or E4 allele than in
carriers of E3 allele, at least among men and also the
presence of E2 allele was related to lower and the E4 al-
lele to higher level of total and LDL cholesterol in
plasma relative to those with the E3 allele [37]. Although
our abnormal WC subgroup of T2DM patients had
higher triglycerides level than the diabetics with normal
WC, there were no significant correlation between apo E
gene polymorphism and triglycerides level in multivari-
ate regression. This finding is in agreement with most
studies that have been done in European diabetic
patients [10,44,45], but it is in contrast to studies on dia-
betic patients among Asian populations [46-48] which
higher level of triglycerides in carriers of E2 allele have
been reported.
In our study, the probability of being obese (BMI ≥ 30)
was increased significantly in women, which was inde-
pendent of apo E polymorphism or diabetes. This par-
ameter is known to influence lipid metabolism or
insulin resistance and may interfere with genetic factors.
The influence of lifestyle on apo E polymorphism was
clearly shown in two parts of Belgium [49]. Although
apo E has long been known as athero-protective and in
excess of circulating lipids apo E would be expressed as
a key peripheral contributor to the development of
obesity and related metabolic dysfunctions. There are
some reports in contrast to our finding. Data from the
Atherosclerosis Risk in Communities (ARIC) study,
showed that apo E genotypes were associated with BMI
in the order of apo E4 < apo E3 < apo E2 [50]. Another
epidemiological study showed that, in older women
with a family history of diabetes, apo E4 /E 4 and
apoE3/E4 genotypes were correlated with increased
waist circumference and obesity [26].
In this study, we observed that there were sex-specific
effects on anthropometric measures. For example, ab-
normal WC was more prevalent in females both in dia-
betics and nondiabetics. Also, our data has shown that
the probability of having obesity, central obesity, and
hypercholesterolemia are increased significantly in dia-
betic women independent of apo E polymorphism. The
sex-specific distribution of apo E gene was not differing
significantly between two groups. This might be as a re-
sult of deviation in female/male ratio in our population.
However, gender related differences are difficult to de-
termine due to variations of hormonal status during pre-
and post menopause in women and their effects on
plasma lipid profile [51].
In our patients the probability of having central obesity,
hypertension and hypercholesterolemia was increased
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When we assessed the effect of apo E2 allele on hyper-
cholesterolemia, this trend was equal 0.36 which by con-
sidering the effect of age, this figure was changed to 2.05.
The trend for increasing central obesity in E4 allele car-
riers was 0.22 without considering the effect of age and
changed to 3.08 in presence of age > 50 years. These
results showed the influence of apo E polymorphism on
abdominal obesity and hypercholesterolemia was signifi-
cantly changed in presence age > 50 years. One study was
evaluated this effect on postprandial triglycerides [52].
They found a significant interaction between age and apo
E on postprandial triglycerides. In their study was
unmasked the unfavorable effect of E2 and E4 alleles on
under curve concentration by aging.
As it is expected, we found a significant increase in
blood pressure just at the presence of diabetes and aging.
A positive correlation between total serum cholesterol
level and blood pressure [53] had been shown in
population-based studies; which might imply the effect
of apo E genotype [54]. However, we didn’t find any sig-
nificant association between apo E genotype and hyper-
tension in our study which could be also due to the
variation in sex distribution.
In this study, there was no information about diet of
our patients therefore we don’t have any precise explan-
ation for these differences. Because our study was car-
ried out in a small population, therefore the effects
observed might not be subject to generalization. The
possible contribution of such association to the observed
relationship between apo E4 and abdominal obesity also
remains to be clarified by prospective studies.Conclusion
In summary, the present study shows low frequency of the
E2 and E4 alleles in our study population and indicates that
apo E polymorphism might play a role in determining
plasma lipids levels. The significant inter-relation between
the apo E polymorphism, abdominal obesity, and change in
total cholesterol levels supports epidemiological findings.
Although lifestyle modification is beneficial in all people,
it may be especially recommendable in women carriers of
E2 allele to modify potentially elevated fasting cholesterol,
and also in carriers of E4 allele to control weight. In
addition, apo E4 allele might be a predictor for CHD in
diabetics by influencing central obesity. Our data suggest
that this risk factor probably exert its atherogenic effects
through diverse mechanisms.Endnote
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